STAG2 and neoplasm: The in vivo distribution experiment confirmed the corollary that T-SA1 with the smallest molecular weight possessed the best tumor targeting property and the least accumulation in other organs compared with trastuzumab even T-SA2, hence a highly specific delivery system.